Wells Fargo assumed coverage of Axsome Therapeutics (AXSM) with an Overweight rating and $163 price target The firm expects the FDA to approve AXS-05 for Alzheimer’s disease agitation. Axsome should submit an application for AXS-05 in Q3 and approval would unlock a $1B-$3B opportunity in additional annual peak sales revenue, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Positive Outlook for Axsome Therapeutics Amidst SYMBRAVO’s Market Expansion and Patent Strength
- Axsome Therapeutics Receives Paragraph IV Certification Notice
- Axsome Therapeutics management to meet with Needham
- Axsome Therapeutics: Strong Sales Performance and Promising Growth Trajectory Reinforce Buy Recommendation
- Axsome Therapeutics: Strong Growth Prospects and Strategic Investments Justify Buy Rating